Fund moves
From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 31, 2025 · Filed Feb 4, 2025
The CEO of Zentalis Pharmaceuticals paid $49K out of pocket for Zentalis Pharmaceuticals shares. 3 other people at Zentalis Pharmaceuticals bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$49,345
Shares × reported transaction price
$25K–$100K
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
4 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2024 ($8.19M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-30. The proxy names this person as CEO for that year. A size comparison, not a judgement
54 days before results of Mar 26, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Fund moves
From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Feb 6, 2025 · filed 6 days later
Zentalis Pharmaceuticals's Chief Medical Officer paid $46K out of pocket for Zentalis Pharmaceuticals shares. 3 other people at Zentalis Pharmaceuticals bought some too, in the same month. Shares held went up 120% with this purchase.
Andrea Paul (Chief Legal Officer) sold ~$23K of Zentalis Pharmaceuticals
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.